Cancer

February 27, 2026

Demographic and histologic factors influence risk of colon polyp recurrence

Vanderbilt Health study supports shift toward dynamic surveillance that extends monitoring for patients with specific demographic and histologic risk profiles.

By Leigh MacMillan
February 18, 2026

Patient with melanoma receives tumor-infiltrating lymphocyte therapy

The highly personalized treatment is currently approved for patients with advanced stages of melanoma whose tumors have grown despite immunotherapies and/or targeted therapies.

By Tom Wilemon
Before being sedated, Aaron Davis gives a thumbs up with his surgical team. (photo by Donn Jones)
February 12, 2026

Vanderbilt Health celebrates milestone for novel histotripsy procedure 

Appealing to patients for its noninvasive nature, it avoids many of the traditional drawbacks of surgeries that use incisions, including pain management. 

By Evan Dorian
John Bailey (courtesy/Sallie Bailey)
February 10, 2026

Wife of cholangiocarcinoma patient makes gift in honor of husband

After moving to Nashville in 2011, Sallie and John chose Vanderbilt Health for their care because they valued being part of a teaching hospital.

By Camille Amadeo Savell
(iStock)
February 4, 2026

Clinical trial led by Vanderbilt Health seeks to refine lung cancer biopsy standards

The development of better biopsy approaches is driven by the fact that lung cancer kills more than 130,000 Americans annually, and survival depends on early diagnosis, which requires biopsy to be definitive.

By Jill Clendening
January 12, 2026

Guide published for outpatient cancer treatment with bispecific antibodies

Vanderbilt-Ingram was among the first in the nation to establish outpatient protocols for another personalized immunotherapy, CAR-T.

By Tom Wilemon
January 8, 2026

Patients with clonal hematopoiesis have increased heart disease risk following cancer treatment 

Study supports the potential benefits of screening patients for CHIP before they undergo cancer treatment so they can be more closely monitored for heart complications.
By Tom Wilemon
January 7, 2026

Study identifies potential target for blood cancer treatment, prevention

The findings could lead to new treatments for blood cancers, which kill an estimated 23,540 people in the United States every year.
By Bill Snyder
December 12, 2025

Lucy Spalluto and Jennifer Lewis awarded $1 million lung cancer screening grant

Lung cancer is the leading cause of cancer death in the United States, with incidence higher in veterans compared to the civilian population.
By Derek Scancarelli
December 8, 2025

Vanderbilt research community mourns loss of longtime colleague Anna Means

In addition to her research, Dr. Means mentored dozens of undergraduate, graduate and postdoctoral students, research staff and faculty.
By Bill Snyder
December 8, 2025

Interim data reported for multiple myeloma off-the-shelf CAR-T therapy  

Vanderbilt-Ingram Cancer Center accrued the most patients nationwide for the clinical trial for P-BCMA-ALLO1 – a chimeric antigen receptor T cell therapy (CAR-T) derived from healthy donors’ white blood cells.
By Tom Wilemon
December 4, 2025

Vanderbilt-Ingram researchers present cancer advancements at ASH 2025 

Established in 1958, ASH is the world’s largest professional organization for clinicians and scientists who study blood diseases. 
By Tom Wilemon
December 3, 2025

Large-scale integration of genomics, proteomics and clinical records identifies cancer risk proteins and potential therapeutics

A new study identifies previously unreported protein biomarkers and candidate drug targets across six major cancer types and highlights approved drugs with potential cancer preventive effects.
By Leigh MacMillan